Inhibitors of SEMA3C could also be combined with other cancer therapeutics including RTK inhibitors, taxanes, and antagonists of the AR axis in the case of PCa, to assess the possibility of synergy. This evidence concerns the gene SEMA3C and posterior cortical atrophy.